Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

RCEL - AVITA Medical, Inc. So'nggi Yangiliklar | Finranks

Home

RCEL

(RCEL)

NCM – Real vaqt narxi. Valyuta: USD

3.82

-0.04 (-1.04%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

3.83

+0.01 (0.26%)

Bozordan keyin: Mar 27, 2026, 7:36 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O'Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025.

Avita Medical: Set Up For A Turnaround

Avita Medical: Set Up For A Turnaround

Avita Medical has an innovative automated wound-healing regenerative system called RECELL Go that uses a small patient skin sample to seed an 80x larger wound. This high-margin product works faster than the standard of care and provides superior results, incentivizing burn and trauma centers to adopt the device. Complementary new products, PermeaDerm and Cohealyx, vertically integrate the wound bend and provide lucrative synergies.

Videolar

No Data

There is no data to display

Press-relizlar

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference

VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O'Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025.

AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025.

AVITA Medical Announces Changes to its Board of Directors

AVITA Medical Announces Changes to its Board of Directors

Veteran healthcare executive Joe Woody joins the Board Lou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025.